Immunotherapy of human cancers with tumor-infiltrating lymphocytes and systemic infusions of interleukin-2

Affiliations

J T Kurnick. Cancer Invest. 1990.

. 1990;8(2):317-8.

doi: 10.3109/07357909009017604.

No abstract available

Similar articles

Treatment of patients with advanced cancer using tumor-infiltrating lymphocytes and interleukin 2.
Kradin R, Dubinett S, Mullin J, Boyle L, Strauss HW, Bourgoin PM, Preffer FI, Kurnick J. Kradin R, et al. Transplant Proc. 1988 Apr;20(2):336-8. Transplant Proc. 1988. PMID: 3259036 No abstract available.
Immunotherapy of cancer with interleukin-2 and lymphocytes (LAK or TIL).
Parmiani G. Parmiani G. Pharmacol Res. 1992 Sep;26 Suppl 2:104-5. doi: 10.1016/1043-6618(92)90619-m. Pharmacol Res. 1992. PMID: 1409264 No abstract available.
Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study.
Topalian SL, Solomon D, Avis FP, Chang AE, Freerksen DL, Linehan WM, Lotze MT, Robertson CN, Seipp CA, Simon P, et al. Topalian SL, et al. J Clin Oncol. 1988 May;6(5):839-53. doi: 10.1200/JCO.1988.6.5.839. J Clin Oncol. 1988. PMID: 3259261
Mechanisms of immunologic antitumor therapy: lessons from the laboratory and clinical applications.
Lotze MT, Custer MC, Bolton ES, Wiebke EA, Kawakami Y, Rosenberg SA. Lotze MT, et al. Hum Immunol. 1990 Jun;28(2):198-207. doi: 10.1016/0198-8859(90)90020-p. Hum Immunol. 1990. PMID: 2190952 Review.
Interleukin-2 and the development of immunotherapy for the treatment of patients with cancer.
Rosenberg SA. Rosenberg SA. Cancer J Sci Am. 2000 Feb;6 Suppl 1:S2-7. Cancer J Sci Am. 2000. PMID: 10685650 Review. No abstract available.